Treatment options for HUS secondary to Escherichia coli O157:H7. (Q33383031)

26 July 2017

1 reference

title

Treatment options for HUS secondary to Escherichia coli O157:H7. (English)

1 reference

26 July 2017

1 reference

Martin Bitzan

1

1 reference

26 July 2017

1 February 2009

1 reference

Kidney International. Supplement

26 July 2017

1 reference

26 July 2017

112

1 reference

26 July 2017

S62-6

1 reference

Predictors of fatality in postdiarrheal hemolytic uremic syndrome

26 July 2017

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Prospective surveillance of Canadian children with the haemolytic uraemic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Serotypes, virulence genes, and intimin types of Shiga toxin (verotoxin)-producing Escherichia coli isolates from human patients: prevalence in Lugo, Spain, from 1992 through 1999.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Escherichia coli O157:H7 infection in nursing homes: review of literature and report of recent outbreak

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Disease burden in The Netherlands due to infections with Shiga toxin-producing Escherichia coli O157.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Economic cost of illness due to Escherichia coli O157 infections in the United States

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Hemolytic uremic syndrome in children in northern India

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Hemolytic uremic syndrome; pathogenesis, treatment, and outcome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Epidemiology of acute kidney injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Risk factors for sporadic Shiga toxin-producing Escherichia coli infections in children, Argentina

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Differential intracellular transport and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide-containing lipid assemblies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Shiga toxin 1 induces apoptosis through the endoplasmic reticulum stress response in human monocytic cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

The pathophysiology of the hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Role of the renin angiotensin system in TNF-alpha and Shiga-toxin-induced tissue factor expression

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Verotoxin (shiga toxin) sensitizes renal epithelial cells to increased heme toxicity: possible implications for the hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Shiga toxin 1 causes direct renal injury in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Cardiomyopathy: a late complication of hemolytic uremic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Pulmonary hemorrhage complicating a typical hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Diabetes during diarrhea-associated hemolytic uremic syndrome: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Preventing household transmission of Shiga toxin-producing Escherichia coli O157 infection: promptly separating siblings might be the key

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

The CI repressors of Shiga toxin-converting prophages are involved in coinfection of Escherichia coli strains, which causes a down regulation in the production of Shiga toxin 2.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Strategies to reduce person-to-person transmission during widespread Escherichia coli O157:H7 outbreak

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Shiga toxin 1-induced cytokine production is mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like THP-1 cell line

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Role of p38 MAP kinase pathway in a toxin-induced model of hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Development of humanized monoclonal antibody TMA-15 which neutralizes Shiga toxin 2.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.624

7 January 2021

Identifiers

DOI

10.1038/KI.2008.624

1 reference

release_fhhhy466dzgxhka257t6jnh76q

26 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fhhhy466dzgxhka257t6jnh76q

24 November 2022

mapped directly with Wikidata item

PubMed ID

19180140

1 reference

PubMed ID

19180140